Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Clinical Study to Evaluate ANX005 in Participants With Guillain Barre Syndrome

Neurology
Bhavesh Trikamji
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barre Syndrome
Brain - Neurologic/ Psychologic
Neuromuscular Diseases

Study Description

Eligibility

  1. Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.
  2. Onset of GBS-related weakness less than or equal to 10 days before start of infusion on Day 1
  3. GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.

Key

  1. Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.
  2. Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.

Other protocol-defined criteria may apply.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.